Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: A randomised, controlled trial

✍ Scribed by Michael Cullen; David Morgan; Walter Gregory; Martin Robinson; Dennis Cox; Damian McGivern; Michael Ward; Michael Richards; David Stableforth; Andrew Macfarlane; Jennifer Stirland; Charlotte Woodroffe; John Macfarlane; John Fletcher; Dewey Davies

• Book ID: 104715290
• Publisher: Springer
• Year: 1986
• Tongue: English
• Weight: 388 KB
• Volume: 17
• Category: Article
• ISSN: 0344-5704
• DOI: 10.1007/bf00306746

✦ Synopsis

Since March 1980, 309 patients with anaplastic small cell carcinoma of the bronchus (ASCB) have received remission induction therapy prior to randomisation to maintenance (M) or no maintenance (NM) chemotherapy. Induction therapy consisted of six courses of vincristine, doxorubicin and cyclophosphamide (VAC) given IV every 3 weeks. Those with limited disease also received mediastinal irradiation. Consenting patients with no unequivocal residual disease were randomised to have no further treatment until relapse or a further eight courses of VAC, at a lower dosage, every 4 weeks. Patients failing to achieve randomisation status received palliative treatment only. The median survival for all patients with limited disease (LD) is 363 days and that for patients with extensive disease (ED) is 272 days (P less than 0.00001). Sixty-one patients with ED were randomised. Those having maintenance chemotherapy lived significantly longer (median 372 days) than those who did not continue therapy (median 259 days) (P = 0.006). An imbalance in the proportion of 'complete remitters' randomised to maintenance therapy does not account for this difference. There is no significant difference between the M and NM groups in the 32 randomised LD patients. Continuing treatment during remission with agents used to induce the remission can prolong survival in patients with extensive stage ASCB.